Genkyotex (Euronext Paris & Brussels: FR0013399474 –GKTX), a biopharmaceutical company and the leader in NOX therapies, announced the closing of the acquisition by Calliditas Therapeutics AB (“Calliditas”; Nasdaq OMX ...
Genkyotex (Euronext Paris & Brussels: FR0013399474 –GKTX), abiopharmaceutical company andleader inNOXtherapies, today announced that its lead drug candidate, setanaxib, has been granted orphan drug designation (ODD) ...
Geneva, Switzerland,21July2020 –08:00amCEST –GeNeuro(Euronext Paris: CH0308403085 –GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune disease ...
Geneva, Switzerland, June 25, 2020–7:30 amCEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune dis ...
NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting ...
Geneva, Switzerland, April 21, 2020–7:30am CEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenera ...
